Literature DB >> 22982433

Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Guérin substrains.

Silvia Secanella-Fandos1, Marina Luquin, Esther Julián.   

Abstract

PURPOSE: Evolutionarily early and late bacillus Calmette-Guérin substrains are genetically distinct, showing different antigenic determinants. While it was suggested that this may influence the immunostimulatory effects of bacillus Calmette-Guérin as a vaccine in the context of tuberculosis, to our knowledge the impact of these genetic differences on the antitumor activity of bacillus Calmette-Guérin remains unknown. We compared the direct antitumor capacity and the ability to trigger cytokine production of 8 evolutionarily early and late BCG substrains in urothelial bladder cancer cell lines.
MATERIALS AND METHODS: The T24, J82 and RT4 bladder tumor cell lines were cultured with different doses of 3 evolutionarily early bacillus Calmette-Guérin substrains (Japan, Moreau and Russian) and 5 evolutionarily late strains (Connaught, Danish, Glaxo, Phipps and Tice). The inhibition of cell proliferation at different time points and the production of interleukin-6 and 8 in cell culture supernatants were measured.
RESULTS: For T24 and J82 cells Russian and Connaught induced the highest inhibition of cell proliferation and cytokine production, triggering values up to threefold higher than the other bacillus Calmette-Guérin strains. In contrast, Glaxo and Phipps (for T24 cells) and Glaxo and Tice (for J82 cells) were the least efficacious. For RT4 all bacillus Calmette-Guérin strains inhibited cell proliferation to a similar extent and induced low levels of only interleukin-8 except the Danish and Glaxo strains, which were less efficacious.
CONCLUSIONS: Russian and Connaught, which are evolutionarily early and late substrains, respectively, are the most efficacious bacillus Calmette-Guérin strains for inhibiting cell proliferation and inducing cytokine production. Glaxo is the least efficacious strain.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22982433     DOI: 10.1016/j.juro.2012.09.049

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

Review 1.  BCG immunotherapy for bladder cancer--the effects of substrain differences.

Authors:  Christine Gan; Hugh Mostafid; Muhammad Shamim Khan; David J M Lewis
Journal:  Nat Rev Urol       Date:  2013-09-17       Impact factor: 14.432

2.  The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer.

Authors:  J Alfred Witjes; Guido Dalbagni; Robert J Karnes; Shahrokh Shariat; Steven Joniau; Joan Palou; Vincenzo Serretta; Stéphane Larré; Savino di Stasi; Renzo Colombo; Marek Babjuk; Per-Uno Malmström; Nuria Malats; Jacques Irani; Jack Baniel; Tommaso Cai; Eugene Cha; Peter Ardelt; John Varkarakis; Riccardo Bartoletti; Martin Spahn; Francesca Pisano; Paolo Gontero; Richard Sylvester
Journal:  Urol Oncol       Date:  2016-09-14       Impact factor: 3.498

Review 3.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

4.  Are there differences among bacillus Calmette-Guérin (BCG) strains regarding their clinical efficacy in the treatment of non-muscleinvasive bladder cancer? The jury is still out but the answer is likely no.

Authors:  Guan Hee Tan; Cynthia Kuk; Alexandre R Zlotta
Journal:  Can Urol Assoc J       Date:  2019-07-23       Impact factor: 1.862

Review 5.  Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.

Authors:  Neelam Mukherjee; Esther Julián; Jordi B Torrelles; Robert S Svatek
Journal:  Vaccine       Date:  2021-10-07       Impact factor: 4.169

Review 6.  Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.

Authors:  Yuan-qiang Zheng; Youssef W Naguib; Yixuan Dong; Yan-chun Shi; Shorgan Bou; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2015       Impact factor: 5.217

7.  Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule.

Authors:  Kanuj Malik; Anand Raja; Lalgudi Subramaniam Ravishankar; Kathiresan Narayanaswamy; Venkatraman Radhakrishnan; Tenali Gnana Sagar
Journal:  Indian J Surg Oncol       Date:  2021-09-09

8.  Methyl-hydroxylamine as an efficacious antibacterial agent that targets the ribonucleotide reductase enzyme.

Authors:  Esther Julián; Aida Baelo; Joan Gavaldà; Eduard Torrents
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

Review 9.  Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions.

Authors:  Kuan-Wei Shih; Wei-Chieh Chen; Ching-Hsin Chang; Ting-En Tai; Jeng-Cheng Wu; Andy C Huang; Ming-Che Liu
Journal:  Aging Dis       Date:  2021-06-01       Impact factor: 6.745

10.  Mycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment.

Authors:  Estela Noguera-Ortega; Núria Blanco-Cabra; Rosa Maria Rabanal; Alejandro Sánchez-Chardi; Mónica Roldán; Sandra Guallar-Garrido; Eduard Torrents; Marina Luquin; Esther Julián
Journal:  Sci Rep       Date:  2016-06-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.